Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer

被引：9
作者：
Lin, Jianqing [1 ]
Kelly, William K. [1 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期
关键词：
Antiangiogenic therapy; Prostate cancer; Angiogenesis; Treatment; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; TUMOR ANGIOGENESIS; C-MET; ANDROGEN RECEPTOR; VEGF EXPRESSION; COMBINATION; BEVACIZUMAB; DOCETAXEL; SUNITINIB;
D O I：
10.1016/j.ucl.2012.07.010
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.
引用
收藏
页码：547 / +
页数：15
相关论文
共 75 条
  • [1] Adesunloye B, 2012, J CLIN ONCOL S5, V30
  • [2] Alfiky A, 2010, BEVACIZUMAB ADV PROS, V207-14
  • [3] Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
    Alva, Ajjai
    Slovin, Susan
    Daignault, Stephanie
    Carducci, Michael
    DiPaola, Robert
    Pienta, Ken
    Agus, David
    Cooney, Kathleen
    Chen, Alice
    Smith, David C.
    Hussain, Maha
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 749 - 757
  • [4] [Anonymous], CANCER
  • [5] Tumorigenesis and the angiogenic switch
    Bergers, G
    Benjamin, LE
    [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 401 - 410
  • [6] The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer
    Boddy, JL
    Fox, SB
    Han, C
    Campo, L
    Turley, H
    Kanga, S
    Malone, PR
    Harris, AL
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (21) : 7658 - 7663
  • [7] Bok RA, 2001, CANCER RES, V61, P2533
  • [8] IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT
    BOTTARO, DP
    RUBIN, JS
    FALETTO, DL
    CHAN, AML
    KMIECIK, TE
    VANDEWOUDE, GF
    AARONSON, SA
    [J]. SCIENCE, 1991, 251 (4995) : 802 - 804
  • [9] Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model
    Bozec, A.
    Sudaka, A.
    Toussan, N.
    Fischel, J.-L.
    Etienne-Grimaldi, M.-C.
    Milano, G.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (10) : 1703 - 1707
  • [10] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
12345678